Peptide arrays for screening cancer specific peptides

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Phage display has identified peptides for cancer targeting.
• A need exists for efficient screening methods to optimize these peptides.
• Understanding peptide-cell interactions is crucial for developing cancer therapeutics.

Purpose of the Study:

• To develop and validate a novel peptide array method for screening cancer cell-specific peptides.
• To identify novel peptides with high binding affinity to human cancer cell lines.
• To compare the binding specificity of identified peptides against noncancerous control cells.

Main Methods:

• Synthesis of 70 peptides in an array format on a cellulose membrane.
• Development of a direct peptide-whole cell interaction assay using CyQUANT fluorescence.
• Validation of top-performing peptides using confocal microscopy and flow cytometry after FITC labeling.

Main Results:

• Identification of at least five new peptides with up to 3-fold higher affinity for MDA-MB-435 and MCF-7 cancer cells compared to the p160 peptide.
• Demonstrated minimal binding of these peptides to human umbilical vein endothelial cells (HUVECs).
• Confirmed high and specific affinity of an 11-mer peptide (peptide 11) and a 10-mer peptide (peptide 18) for cancer cells.

Conclusions:

• The peptide array-whole cell binding assay is an effective complementary method to phage display for cancer peptide screening.
• Identified peptides, particularly peptide 11 and peptide 18, show promise for cancer therapy and diagnosis.
• Peptide 11 targets multiple receptors, while peptide 18 binds the p160 receptor, offering distinct therapeutic strategies.